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DEFINITIONS 
The clinical picture of generalized infection, often 
known as 'sepsis', can range from evidence of infection 
with limited symptoms to septic shock and multiple 
organ failure. The 'sepsis syndrome', a concept defined 
to help clinicians recognize and treat severe infections 
[l], has been judged not sensitive enough to detect all 
severe infections. An alternative approach to the 
definition of septic syndromes was suggested in 1992 
[2] (Table 1). The suggestion was based on the clinical 
suspicion of a continuum between four conditions that 
are easily recognizable: systemic inflammatory response 
syndrome (SIRS); sepsis; severe sepsis; and septic shock. 
The hypothesis was that the recognition of patients 
meeting the clinical criteria for SIRS would help to 
i d e n t i ~  those at risk for sepsis and more severe septic 
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conditions. Such clinical definitions are useful for diag- 
nosis, but it is unlikely that different antibiotics are 
required for different stages of the diseases once 
Table 1 Definitions of septic syndromes 
Systemic 
Inflan~niatory 
Response 
Syndrome (SIKS) Sepsis Severe sepsis Septic shock 
Two or iiiore of SIRS Scpcis Sepsis-induced 
the following: + acwciatcd with hypotension 
>3X"C, infection dyfunction, resuscitation) 
<36"C (positive culture 1iypoperftiw)ii plus 
heart rate for organistii) ahiiormalities, IiypopcrftiLlrion 
>WJ/niiii or hypoten\ion. ~bnortriditiec 
respiratory Hypopcrfusioii 
rate >20/inin abnorni;~litie\ 
W l K  >12x in~lude,  but are 
10''/L or not limited to, 
<4.OX lactic acidosis, 
1O"/L or  oliauria or an 
> 0.10% aciite alteration 
imiiiature 111 niental status 
forms (band 
temperature docuincnted organ (despite fluid 
cells) 
Adapted from definitions described b y  the American College of 
Chest PhysiciandSociety of Critical Care Medicine Consensus 
Conference 121. 
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infection is suspected, and the whole spectrum of 
clinical disease is considered in our recommendations. 
EPIDEMIOLOGY 
In 1990, the US National Center for Health Statistics 
reported that the percentage of discharge diagnoses that 
included bacteremia (either community or hospital 
acquired) increased froin 74 cases per 10 000 patients in 
1978 to 176 per 10 000 in 1987 [3]. The incidence of 
nosocomial bloodstream infection markedly increased 
from 1980 to 1989 in large teaching hospitals par- 
ticipating in the National Nosocomial Infection 
Surveillance System (NNISS) in the USA [4]. Trends 
in pathogen-specific rates of nosocomial bloodstream 
infections in the NNISS study have recently been 
analyzed [4]. These trends were similar to those 
observed in single institutions [5,6]. Based on these 
studies, the rates of nosocomial bloodstream infection 
have increased over the past decade; in one institution 
rates increased from 6.7 to 18.4 per 1000 hospital 
admissions between 1980 and 1992 [5]. Increases in the 
infection rate were mainly due to Gram-positive cocci 
(p<0.001), and yeasts @<0.001), and were essentially 
explained by infections caused by coagulase-negative 
staphylococci (CNS), Staphylococcus aweus ,  enterococci 
and Cand ida  spp. 14-61. 
In Europe, an incidence of 72.3 episodes per 1000 
hospital admissions was reported from Frankfurt, 
Germany [7], and of 8.9 episodes per 1000 hospital 
admissions from Bergen, Norway [8]. Age-adjusted 
death rates for bacteremic sepsis (sepsis associated with 
positive blood cultures) are increasing steadily [9], with 
mortality in nosocomial sepsis higher than in the 
community-acquired disease [lo]. 
The pathogens most often associated with blood- 
stream infections (Table 2) are staphylococci (coagulase 
positive and coagulase negative), streptococci, entero- 
cocci, Enterobacteriaceae (particularly Escherichia coli, 
Klebsiella spp. and Entevobacter spp.), Pseudomonas 
aeruginosa, and, rarely, anaerobes and Cand ida  spp. 
[4,5,11-141. Local epidemiologies vary and the distri- 
bution of pathogens is changing constantly as a result 
of developments in diagnostic and therapeutic pro- 
cedures and the selection pressure from new anti- 
bio tics. 
OUTCOME AND IMPACT 
The crude mortality associated with bloodstream 
infection approximates to 40%, ranging from 12% to 
80% [5,6,10,15-191. In a study ofsurgical intensive care 
unit (ICU) patients [20] with a crude mortality of 50%, 
the mortality attributable to nosocomial bloodstream 
infection was 35% (95% CI=25-45%). Mortalities 
related to pathogen, site of infection and other factors 
in nosocomial and community-acquired cases have 
been established [5,10,21-231. Some reports suggest 
that factors such as age, the presence of pre-existing 
co-morbidities [24], admission to intensive care, dura- 
tion of hospitalization, cancer and neutropenia are 
associated with higher mortality. A study of bacteremic 
patients admitted to a surgical ICU demonstrated that 
the number of evolving organ dysfunctions (developing 
after the initiation of treatment) was the best predictor 
of mortality [19]. 
Table 2 Leading bloodstream isolates recovered in six large studies (n=35 959) 
University of Iowa PEG r PEG I1 
St Thomas’ Hospital NNISS Hospitals and Clinics, Germany and Germany and 
London, UK (11) USA (4) USA (5) Austria (12) Austria (13) European 
1969-1988) 1980-1989 1983-1 992 1983-1985 1991-1992 (n=3 440) 
(PI+ 268) (n=l l  185) (Y1=3 464) (n=8 999) (n=4 603) multicenter (14) 
Coagulase-positive 
staphylococci 
Coagulase-negative 
qtaphylococci 
Streptococci 
Eriterococci 
E. c d i  
Enfrroburter spp. 
KIt-bsidla spp. 
Pseudomonas aerqinor  
Fungi 
Anaerobes 
15 
4 
13 
<1 
22 
2 
7 
a 5 
0.1 
0.4 
5 
25 
4 
8 
7 
5 
4 
5 
8 
16 
26 
6 
4 
11 
6 
8 
9 
7 
3 
19.9 
10.4 
6.7 
5.5 
22.0 
4.6 
5.9 
4.8 
1.9 
20.4 24 
9.3 13 
7.5 
5.3 
23.9 29 
3.6 14” 
5.4 
4.2 9b 
1.4 
Studies 4 and 5 include only nosocomial bloodstream infections. 
dKlebsiella /Enterobuctev qpp. 
hPretrdomonas qpp. 
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Importantly, about half the patients with severe 
sepsis or septic shock have negative blood cultures 
[18,25], and mortality rates in patients with septic 
shock with or without positive blood cultures are 
similar in most studies [15-18,251. Thus, severe and 
frequently fatal septic conditions, whether or not the 
blood cultures are positive, force the clinician to start 
enipirical antimicrobial therapy based on his or her 
individual experience and knowledge of the local 
epidenliologic trends. 
ETIOLOGY OF SEPSIS IN NEUTROPENIA 
The patient with neutropenia (neutrophil count 
< 1000 cells/ninr3) has a high risk of bactereinic 
infection. Both severity and duration of the neutro- 
penic event will affect this risk. The most significant 
pathogens causing bloodstream infection in neutro- 
penic patients are shown in Table 3 [26]. 
The etiology of neutropenic sepsis has changed 
strikingly over the last 20 years. In six consecutive trials 
carried out by the European Organization for Research 
and Treatment of Cancer (EORTC) International 
Antimicrobial Therapy Cooperative Group from 1973 
to 1991, single-organism bactereniias caused by Gram- 
negative bacilli decreased from 71% to 31‘%1, while 
those caused by Gram-positive cocci increased from 
29% to 69% [27]. In two consecutive trials carried out 
by the GIMEMA Infection Program in neutropenic 
patients receiving prophylaxis with fluoroquinolones 
(norfloxacin or ciprofloxacin), this trend was even more 
evident [28,29]. Single-organism bacteremias caused by 
Gram-negative bacilli decreased from 36% to 1196, 
whereas bacteremias caused by Gram-positive cocci 
increased from 64% to 89%. In these two trials, the 
most common Gram-positive bloodstream pathogens 
were CNS (44% and 42%, respectively). Infection by 
S. uuwus increased from 8% to 27% and this may be due 
Table 3 
patients with neutropenia 
Organisms causing bloodstream infections in 
Hxter ia  Fungi 
Staphyloroirus cyidermidir 
Staplrylocorrcts aurfws 
Viridans Ftreptococci 
Streptococcus pueumoniae 
Enterococci 
Coyrirhurtcrium jcikeium 
Enterobacteriaceae 
Eschericlzia coli 
Klcbsiella-Euterobactc~Serratia 
Protects spp. 
Preudoinonas aerctginora 
Candida spp. 
Fusavictm spp. 
7?ichosporon spp. 
iMdlasseria f u f u r  
to the development of quinolone resistance in some 
strains [30]. Prophylactic use of fluoroquinolones teems 
also to have favored an increase in the rate of oxacillin 
resistance, documented in 50% of staphylococci iso- 
lated from blood. Bacteremia ,clue to viridans strepto- 
cocci decreased from 41% to 21%; complications 
included acute respiratory distress syndrome, shock 
and, more rarely, endocarditis. Mortality ranged from 
6% to 30% [31]. 
The main pathogens causing neutropenic sepsis are 
often resistant to methicillin, and many strains are 
resistant to both ceftazidime and amikacin, antibiotics 
often used empirically in this setting. New treatnients 
for Gram-positive infections are demanded by the 
changing epidemiology, poor antibiotic susceptibility 
of blood isolates [28-311, ;and poor response to 
empirical treatment with ai-ninoglycosides and p- 
lactam regimens [32]. 
Although it was the frequency and severity of 
infections caused by Grain-negative bacteria that led to 
the widespread use of empirical antibiotic therapy in 
patients with neutropenia and fever, the relative 
frequency of these infections has declined during the 
last decade. In the two GIMER4A trials [28,29], single- 
organism Gram-negative bacteria accounted for only 
3.2% and 1.6%, respectively, of all neutropenic 
episodes. The decrease in relative importance of these 
pathogens appears to be re1ai:ed to the prophylactic 
use of fluoroquinolones [28] It should be stressed, 
however, that widespread and long-term prophylactic 
use of quinolones may fabor the emergence of 
quinolone-resistant Gram-negative bacteria [33,34]. In 
the GIMEMA trials, the few reported cases of Gran- 
negative infection were caused mainly by quinolone- 
resistant I! ueruginosa and other Pseudoinonas spp. 
that were also resistant (6@-70%) to aminoglycosidcc 
(amikacin) and third-generation cephalosporins (cefta- 
zidinie). The mortality rate associated with Gram- 
negative bactereniia is five times that associated with 
Gram-positive infection [28] and relates mainly to 
early septic shock. The goal of empirical antibiotic 
therapy is, therefore, to protect the neutropenic patient 
from early death due to Gram-negative bacterial 
infection. 
CURRENT PRACTICE 
Correct initial antimicrobial treatment has been shown 
to reduce the mortality associated with bacteremic 
sepsis [21,35,36]. A recent study investigating the role 
of anti-endotoxin monoclonal antibodies in sepsis 
confirmed that inappropriate antimicrobial therapy was 
strongly associated with death in patients with Gram- 
negative bactereniia 1371. Clearly, it is important to use 
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Table 4 Community-acquired sepsis-proposals for empirical antibacterial treatment 
Patient factors Likely infecting organisms Empirical antibiotic therapy 
No known risk factors S. aureus, Co-amoxiclav, second or third-generation cephalosporin 
colifornis, + 
pneumococci, aininoglycoside 
group A streptococci, or 
Ncisseria rnrningitidis glycopeptide or cliridamycin 
+ 
aminoglycoside or quinolone 
Huiiioral defect 
Cellular dcfcct 
Pneumococci, Ampicillin, if resistance to ampicillin IS low 
Haemopkilus irlflnenzae, or 
Neisseria meningitidis third-generation cephalosporin 
Salmonella spp., Quinolones 
Other enteric bacteria, or 
Listwia spp. third-generation cephalosporin, 
or 
aztreonam 
Ampicillin+ gentamicin if Lirteria spp. suspected 
Additional risk factors (prosthesis, Staphylococci, 
intravenous catheters, intravenous Streptococci 
drug abusers) colifor ms , 
anaerobes, 
Caridida spp. 
Isoxazolyl penicillin 
First-generation cephalosporin for periicdin allergy 
Glycopeptide If methicillin resistance > 5% 
~ 
Methicillin resistance > 5% refers to institutions (or communities in rare instances) where the prevalence of inethicillin resistance among 
S. anreus strains is greater than 5%. 
appropriate antibiotics, although unequivocal choices 
are not available and treatment is often based on the 
most likely pathogen. The focus of infection may be 
obvious, influencing the choice of antibiotic, but more 
commonly a broad-spectrum antimicrobial regimen 
appropriate to the local epidemiology is chosen. 
Several sets of recommendations are currently 
available, including those by Sanford [38], Wood 139) 
and, for neutropenia, the Working Committee of the 
Infectious Diseases Society of America [40] arid the 
EORTC [27]. 
Current European practice has been studied in a 
recent survey of hospitals in France, Germany, Italy, 
Spain and the UK [41]. The study included 336 
patients (1 11 neutropenic, 225 non-neutropenic) with 
sepsis, most of whom were at  least seriously ill at  the 
start of treatment. Nosocornial infection was respon- 
sible for 33% of the episodes of sepsis in neutropenic 
patients, and 50% of the infections in non-neutropenic 
patients. Postoperative infections accounted for 18% 
of the 225 episodes of sepsis in the non-neutropenic 
patients. Overall, treatment was 84% successful, 
although changes in therapy were quite frequent. Most 
initial treatment (90%) was empirical, but positive 
cultures and susceptibility test results were eventually 
obtained for 65%) of patients. Gram-positive and Gram- 
negative organisms were approximately equally repre- 
sented [41]. The treatment failure rate was higher for 
Enterobacteriaceae and fungi. 
Aminoglycosides as part of combination therapy 
were the most frequent choice for the empirical 
treatment of neutropenic patients, followed by ureido- 
penicillins, third-generation cephalosporins, glyco- 
peptides and quinolones. The extent of combination 
therapy with an aminoglycoside varied from 35% in 
France to 16%) in Italy; hematology-oncology wards 
and ICUs were the two largest users of combination 
therapy as a proportion of total usage (> 50%) [41]. For 
non-neutropenic patients, the empirical choices were 
most likely to be penicillins, third-generation cephalo- 
sporins, quinolones and aminoglycosides; amino- 
glycosides were used mostly (>85%) in combination 
therapy. 
Empirical treatment of suspected Gram-positive 
sepsis (before culture results become available) usually 
consisted of ureidopenicillins or quinolones in com- 
bination with aminoglycosides in neutropenic patients, 
and antistaphylococcal penicillins, anipicillin or amino- 
glycosides in non-neutropenic patients [41]. Amino- 
glycosides as part of combination therapy were the 
most frequent empirical choice for conditions where 
there was no indication of the responsible agent, with 
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Table 5 Nosocoiiiial sepsis-proposals for empirical antibacterial treatment 
Patient factors Likely infecting organisms Empirical antibiotic therapy 
Risk of multiresistance (mechanical E.  ioli, Third-generation cephalosporin 
ventilation, previous antibiotic Klebsiella spp., or 
treatment, niajor surgery and Entcrubacter spp., carbapeiiem 
prolonged stay in an 1CU) I! aeruginosa, or 
MRSA, cnterococci high-dose ciprofloxacin+ aminoglycoside 
(+ a glycopeptide if inethicillin resistance is c ~ i n m o n )  
No special riTk of multi-resistance 
Surgical patients recoveriiig from E. di, Piperacillin/tazobnctarn 
abdominal surgery Klebsielfa spp., or 
tinterobacter spp., inetronidazole + third-generation cephalosporin 
I ?  aerccy+osa, enterococci or 
metronidazole + quinolorie 
or 
carbapeneni 
Prmthetic device MKSA, Penicillinase-stable penicillin 
other staphylococci or 
glycopeptide 
Non-surgical risk factors E. CLJl i ,  Co-amoxiclav + aiiiinoglycoside 
I<lrbsiclla spp., or 
Enfmdmfer sppp., 
I? a e n q i m s a ,  cnterococci 
Second- or third-generation cephahporin +aininoglycoside 
MRSA, methicilliii~rcsistdnt S. uureccs 
glycopeptides being used much more frequently in 
neutropenic than in other patients. 
It is of note that the treatments in use, both 
empirical and for documented infection, are diverse. 
Many regimens do not adequately cover Gram-positive 
organisms, particularly in neutropenic and inimuno- 
compromised patients. 
PROPOSALS FOR THE EMPIRICAL TREATMENT OF 
COMMUNITY-ACQUIRED SEPSIS 
The infecting organism in community-acquired sepsis 
will depend not only on the local epideiiiiology and the 
particular patholoL9, but also on patient factors. 
Proposals for treatment are based on the most likely 
infecting organisnis and are summarized in Table 4. 
Previously healthy adults 
In these patients without any clear focus of infection, 
the organisms to consider include mainly S.  anreus, 
Eriterobacteriaceae, pneumococci, group A strepto- 
cocci and Neisscvia nzeningitidis. Possible therapeutic 
options include co-amoxiclav, or a second- or third- 
generation cephalosporin plus an aniinoglycoside, or 
clindainycin, or glycopeptide (the last two in con -  
bination with an aminoglycoside or quinolone). 
lmmunocompromised individuals 
The infecting organisms in irnmunocoiiipromised 
individuals will vary depending on the type of iiiiniune 
defect. Pneumococci, Haemopli i lus  i~tflitenzae or iY 
meningitidis may be associated with a humoral iminune 
defect. A third-generation cephalosporin (e.g. cefo- 
taxinie or ceftriaxone) should be considered. In thosc 
countries where local resistance to anipicilliri is low, 
ampicillin may be considered. Organisms such as 
Salmonella spp. and other entvric bacteria are seen in 
patients with a cellular iniinunc defect. A quinolorie or 
a third-generation cephalospoi-in or aztreonam can be 
used as first-line therapy. 
Ampicillin plus gentarnicin should be used when 
infection caused by Listevia spp. is suspected. Quino- 
lones or third-generation cephalosporins are inappro- 
priate for Listeria spp. Patients who are most at risk of 
infection with Listevia spp. include the elderly, and 
those with alcoholism, diabetes and additional factors 
aEecting the host innnune response. 
Patients with additional risk faclors 
This group includes intravenous drug abusers, and 
patients with chronic renal f.iilure and prostheses or 
intravenous catheters. In such patients, orgaiiisiiis such 
as Staphylocorrus spp., including CNS, streptococci, 
Enterobacteriaceae, anaerobes and Cand ida  spp. should 
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be considered as potential pathogens. Treatment of 
these patients should include an isoxazolyl penicillin. 
In the case of penicillin allergy, a first-generation 
cephalosporin can be substituted. If the prevalence of 
niethicillin-resistant S. auveus isolates in the community 
(or in the hospital in case of recent hospital stay) is 
greater than 5'31, a glycopeptide should be used. 
PROPOSALS FOR THE TREATMENT OF NOSOCOMIAL 
SEPSIS 
Proposals for the treatment of sepsis arising from 
nosocomial infections are summarized in Table 5. 
Surveillance cultures could be helpful in decision- 
making in some circumstances, in particular in critically 
ill patients, in whom colonization with nosoconiial 
pathogens precedes infection caused by an identical 
strain in almost half of the cases [42]. The organisms 
to consider include E. coli, Klebsiella spp., Enterobactev 
spp., I? auruginosa, Acinetobacter spp., methicillin-resistant 
staphylococci and enterococci. Risk factors include 
mechanical ventilation, previous antibiotic treatment, 
major surgery and prolonged stay in an ICU. A 
carbapenem or a third-generation cephalosporin should 
be used, in combination with a glycopeptide if methi- 
cillin resistance is common and according to hospital or 
local (ward) epidemiologic data. A high-dose intra- 
venous quinolone plus an aminoglycoside is an 
alternative. Studies are needed to define the potential 
role of cefepinie and cefpirome in the empirical therapy 
of sepsis in critically ill patients. An increase in 
candidenia is being reported from several centers, and 
pre-emptive antifungal therapy should be considered in 
high-risk patients. 
No special risk of multiple antibiotic resistance 
Where there is no particular risk of multiple antibiotic 
resistance, other factors, such as whether the patient 
has undergone surgery or has prosthetic devices, will 
influence antibiotic choice. For patients who have 
undergone abdominal surgery, alternatives are a carba- 
penem alone, or metronidazole plus a third-generation 
cephalosporin or a quinolone, or piperacillin plus 
tazobactam. In a patient with a prosthetic device, a 
penicillinase-stable penicillin or a glycopeptide should 
be used. If there are no other factors to take into 
account, a second- or third-generation cephalosporin 
or co-amoxiclav, plus an aminoglycoside, constitutes 
the treatments of choice. 
EMPIRICAL TREATMENT OF SEPSIS IN NEUTROPENIA 
Cancer patients with febrile neutropenia form a 
heterogeneous group, with differing risk profiles for 
infection-related morbidity and mortality, and hence 
cannot be treated uniformly. 
low-risk neutropenic patients 
Patients with mild neutropenia (> 100 cells/mm") of 
short duration (< lo  days), generally represented by 
those with solid tumors and lymphomas, are considered 
to be at  lower risk of infection. Febrile neutropenia 
may have a better prognosis in these patients if they lack 
adjunctive risk factors [43]. Monotherapy can be used 
to treat this group of patients, depending on local 
epidemiology. The most commonly used therapeutic 
options are third-generation cephalosporins, and then 
carbapenenis or fluoroquinolones. Several alternatives 
to hospital-based therapy have been evaluated in 
such patients. These include early discharge to home 
antibiotic therapy after initial stabilization in the hospital, 
or treatment of the entire febrile episode with intra- 
venous and/or oral antibiotics in the ambulatory setting 
or at home. Fluoroquinolones (ofloxacin, ciprofloxacin), 
with or without co-anioxiclav, proved to be effective 
[44]. Glycopeptide antibiotics should be reserved for 
patients with confirmed Gram-positive infection, not 
responding to the empirical antibiotic therapy; teico- 
planin could be used in the outpatient setting. 
High-risk neutropenic patients 
Profound (< 100 cells/mm3) and persistent (> 10 days) 
neutropenia is the hallmark for patients in the high-risk 
group. Other factors have also been identified as 
predictive of poor outcome [43,45], including: history 
of hospitalization, active, underlying disease, presence 
of other conditions such as hypotension, altered mental 
status, respiratory failure, dehydration, inadequate oral 
intake and gross bleeding. For these patients, the 
recommended empirical antimicrobial therapy is a p- 
lactam with activity against I? aeruginosa (e.g. cefepime, 
ceftazidime, a carbapenem, piperacillin/tazobactam) in 
conibination with anlikacin or another aininoglycoside 
according to local epidemiology. Once-daily amikacin 
with ceftriaxone was as effective and no more toxic 
than multiple daily doses of amikacin and ceftazidiine 
[32]: it should be stressed, however, that in this study 
there were only a few episodes of documented I? 
aevuginosa infections. 
The combination of two p-lactam antibiotics 
(e.g. ceftazidime plus piperacillin, cefoperazone plus 
ticarcillin) has been proposed as an alternative empirical 
treatment in high-risk neutropenic patients to prevent 
the use of an aminoglycoside with associated nephro- 
toxicity. The conibination of two p-lactam antibiotics 
is costly, however, and seems to be related to a risk of 
relapse of Gram-negative infection (e.g. I? aertrginosu), 
emergence of resistant strains and fungal super- 
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infections [46). The regimen inay be useful in elderly 
patients, those with renal failure, those treated with 
nephrotoxic drugs (cisplatin, cyclosporin, ampho- 
tericin 13) or those with impaired hearing or vestibular 
damage. 
Because some third-generation cephalosporins 
and carbapeneiiis have bactericidal activity against the 
Enterobacteriaceae, I? aevq inosa  and some Gram- 
positive organisms, Pizzo supports inomtherapy as a 
safe, cost-effective alternative to conibination regimens 
containing an aininoglycoside [26]. Monotherapy with 
ceftazidinie or carbapenems (iniipenem, nieropenern) 
seems to be a safe and cost-effective alternative to c o n -  
binatiori regimens [47-491; further published clinical 
studies are needed to define the potential role of 
cefepiiiic and cefpironie in the empirical monotherapy 
of febrile neutropenic patients. It should, however, be 
stressed that Graiii-negative bactereinia in patients with 
profound and persistent neutropenia has a better out- 
come if treated with a p-lactani plus aniinoglycoside 
[SO]. 
The need for glycopeptide antibiotic therapy in the 
neutropenic patient is supported by the increasing 
prevalence and resistance of Gram-positive pathogens, 
as well as by the poor response of Gran-positive 
bacteria to p-lactaiii plus aminoglycoside regimens. 
The timing of glycopeptide introduction into the 
treatment regimen is still a matter of debate. The 
arguments for saving glycopeptides for second-line or 
rescue therapy include the low incidence of Gram- 
positive bacteremias in febrile neutropciiic episodes 
(1 S-20%), the effectiveness of ureidopenicillins against 
streptococci and the relatively low early mortality rate 
for (;ran-positive infections. In addition, cost, toxicity 
and, possibly, risk of resistance are lower if these drugs 
are saved for confirmed Gram-positive infections. 
Arguments for the use of glycopeptides as first-line 
therapy include the prevalence of Grain-positive 
infections, the high incidence of strains resistant or 
responding poorly to aininoglycosides and p-lactanis, 
the reduction of secondary infection with Gram- 
positive organisms and lower subsequent use of anipho- 
tericin [3O]. Although survival advantage has not been 
demonstrated when every patient with neutropenia has 
been treated with a glycopeptide antibiotic, it seems 
wise to include a glycopeptide antibiotic in the initial 
empirical regimen if, epidemiologically, rnethicillin- 
resistant S. ULIY~LIS or penicillin-resistant S. vniris is a 
problem [26] or patients are receiving fluoroquinolone 
prophylaxis, have a central venous catheter in place, 
or have severe oral and/or gastrointestinal niucositis 
Both glycopeptides are used in neutropenic patients; 
although teicoplanin is less active in vitro against strains 
~301. 
of CNS than is vanconiycin, both drugs are equally 
effective in vivo [51]. Teicoplanin is, however, l e s ~  
toxic and easier to administer [52]. Kecently a large, 
multicenter randomized, cornpx-ative trial showed that 
teicoplanin, when used for initial empirical antibiotic 
therapy in febrile, neutropenic patients, was as effective 
as vaiicoiiiycin (response rates of Gram-positive 
bactereniia were 92% and 87% respectively), but it was 
associated with fewer side effects [29]. 
Better control of bacterial infections has favorcd a n  
increase in invasive fungal infections in cancer patients. 
Whether those patients with prolonged neutropenia 
niay benefit from antifungal prophylaxis remains 
controversial, in particular with respect to the type, 
dosage and duration of drug therapy for preventing 
fungal infec ti ons . Early empirical antifungal treatment 
in neutropenic patients with sepsis depends upon the 
clinical conditions, the antibacterial regimen rcccived, 
the type of ineasures implemented to reduce environ- 
mental exposure to Arpcqillcrs spp., and whether or not 
antifungal prophylaxis has be,m used. We refer the 
reader to a recent review [53] (of this topic. 
EMERGING RESISTANCE A N D  CONCLUDING 
REMARKS 
Penicilliii-resistant pneuniococci represent an increas- 
ingly coiiinion problem. Among 1500 isolates of 
Strcptacorrtrs pnewmniae collected from outpatients at 
iiiedical centers in the USA bfztween 1994 and 1995, 
23.6% were resistant to penicillin: 14.1'X had 
intermediate resistance (MIC (1.1-1 .O mg/L) and 9.5% 
were highly resistant (MIC 3 2  mg/L) 1541. Similar 
rates of resistance are found in sonie European 
countries (i.e. Spain, Hungary) Many of the penicillin- 
resistant strains are also resistant to other aiitiniicrobials, 
including erythromycin, chloramphenicol and tri- 
methoprim-sulfainethoxazole. Because pneuniococci 
are easily spread from persori to person, this raises 
the specter of nosoconiial diwniination. High-dose 
intravenous penicillin therapy is probably effective for 
sepsis or pneumonia unless the strain is highly recistant; 
in this case, a third-generation cephalosporin (cefo- 
taxirne, ceftriaxone) or a glycopeptide antibiotic should 
be considered. Therapy of meningitis due to penicillin- 
resistant pneuinococci requires cefotaxiine or ceftria- 
xone; vanconiycin, in a dose >40 mg/kg/day, should 
be added if there is a high prevalence of strain5 
with a third-generation cephalmosporin MIC > 1 mg/L. 
The concomitant use of corticosteroid may markedly 
decrease the cerebrospinal fluid penetration of vanco- 
mycin and niay have a lesser effect on ceftriaxone 
but has no effect on rifampin penetration. Meropeneni 
inay represent a useful therapeutic alternative in 
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the treatment of meningitis due to penicillin-resistant 
pneumococci [SS] .  
The incidence of nosocomial infections caused by 
vancomycin-resistant enterococci (VRE) has increased 
dramatically in US hospitals, and those VRE accounted 
for approximately 8% of enterococcal isolates in 1993 
[56]. VRE seem to be widely distributed anlong 
different European countries, with the recent findings 
of community-based patient carriers who have never 
been in hospital [57-601. In Europe, an association 
between resistance to glycopeptides and the use of the 
glycopeptide avoparcin as a feed additive in animals has 
been suggested [57,58]. 
Resistance to glycopeptides mainly concerns 
Euterococcus faecalis and E. faecium, with higher fre- 
quency of resistance found in strains of the former 
species. Three phenotypes have been described: VanA, 
which confers an inducible high level of resistance to 
vanconiycin and teicoplanin; VanB, which confers low- 
or high-level resistance to vancomycin but not to 
teicoplanin; and VanC, which is specific to E. gallinarum 
and E. casselijlavus and confers a low level of resistance 
to vancomycin. A number of hospital outbreaks of 
VRE have been reported; early identification of 
colonized or infected patients and implementation 
of infection control measures are important to limit 
spread. The Centers for Disease Control and Pre- 
vention (CDC, Atlanta) has recently issued guidelines 
for preventing the spread of VRE [61]. These 
guidelines emphasize prudent use of glycopeptides, 
educational programs for healthcare workers, and 
prompt institution of barrier precautions. Vanconiycin 
administration was reported by many studies as a risk 
factor for acquiring VRE [62-651; however, prior 
exposure to multiple antibiotics, including third- 
generation cephalosporins [66,67] and those with 
antianaerobic activity [68], may be equally important 
[63,65,69]. Oral use of glycopeptides should be avoided 
[61]. Antibiotic control efforts are curtailing improper 
vanconiycin use, reducing antimicrobial pressures that 
can give rise to VRE. Control of antimicrobial treat- 
ment must be considered, however, as a daily challenge 
for physicians, in particular when broad-spectrum 
drugs are used. 
Most antibacterial therapy is empirical because the 
patient is clinically infected but the precise infecting 
organism is unknown. Recommendations in the present 
report consider empirical therapy for sepsis that fre- 
quently mandates the use of broad-spectrum agents 
appropriate to the patient's underlying conditions. In 
any ca$e, antimicrobial therapy must be tailored and 
appropriately adapted as soon as the infecting organism 
is known, to prevent overuse of broad-spectrum agents 
and secondary emergence of resistant strains, cuimu- 
lative toxicity, and disappointing treatment failure 
associated with inappropriate use. 
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